The pharmaceutical landscape is rapidly changing as patents for some of the blockbuster drugs of the last decade near expiration and other players try to grab some of the remaining revenues before generic medications flood the market. AstraZeneca (AZN) announced Thursday morning that it has filed a New Drug Application with the FDA for its antiplatelet treatment ticagrelor. The drug is meant to treat major cardiac events in patients with acute coronary syndrome (ACS) a disease that affects 2.4 million Americans according to the American Heart Association.The drug works by keeping platelets in the blood from sticking together which ...

Fourth healthcare stocks that have brushed aside any potential adversity that could arise from future legislation for the sector.

The FDA warns people prescribed to take Plavix -- the world's No. 2-selling drug -- that also taking the stomach-acid medication Prilosec can reduce Plavix's effectiveness as a blood thinner by nearly half.

Bristol-Myers Squibb shares saw gains Monday, the day after the drugmaker announced it was spinning out its remaining interest in its publicly-traded unit Mead Johnson Nutrition Co.

Bristol-Myers Squibb and Merck & Co. led drugs stocks higher early Monday, echoing trading in the broader market.

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by RothmanResearch.com.